- Home
- DPG vs NPCE Comparison
DPG vs NPCE Comparison
Compare DPG & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | NPCE |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 535.3M | 485.6M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DPG | NPCE |
|---|---|---|
| Price | $14.42 | $14.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.33 |
| AVG Volume (30 Days) | 108.1K | ★ 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $99,986,000.00 |
| Revenue This Year | N/A | $25.95 |
| Revenue Next Year | N/A | $0.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $10.45 | $7.56 |
| 52 Week High | $14.96 | $18.97 |
Technical Indicators
Market Signals| Indicator | DPG | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 55.66 | 42.40 |
| Support Level | $12.37 | $9.52 |
| Resistance Level | $14.68 | $16.96 |
| Average True Range (ATR) | 0.22 | 0.83 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 24.68 | 50.16 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.